title: Effect of coronary percutaneous revascularization on interferon-gamma and interleukin-10 producing CD4+ T cells during acute myocardial infarction.
abstract: T lymphocytes play an important role in the induction and progression of acute coronary syndromes (ACS). To gain insight into how different T cell subsets can influence ACS, we analyzed the frequencies of circulating CD4+ T cells producing either pro-inflammatory interferon(IFN)-gamma or anti-inflammatory interleukin (IL)-10 in subjects presenting with ST-elevation myocardial infarction (STEMI). The effect of coronary bare metal (BS) and paclitaxel-eluting stent (PES) on the balance between CD4+IFN-gamma+ and CD4+IL-10+ lymphocytes was also investigated. Peripheral blood mononuclear cells (PBMC) were isolated from 38 consecutive patients with STEMI before and 48 hrs or 6 days after implantation of either BS or PES. Twenty patients with no history of coronary artery disease were included as basal controls. PBMC were stimulated in vitro with anti-CD3/anti-CD28 monoclonal antibodies, and CD4+IFN- gamma+ or CD4+IL-10+ T cells were detected by flow cytometry intracellular staining. The frequency of peripheral CD4+IL-10+ T cells was significantly higher in STEMI patients as compared with controls. Conversely, the frequency of CD4+IFN-gamma+ T lymphocytes did not differ between STEMI and subjects without history of coronary artery disease. Six days after the revascularization procedure, the percentage of CD4+IL-10+ T cells was significantly decreased in BS but not in the PES group, whereas the relative percentage of CD4+IFN-gamma+ T lymphocytes were diminished in both groups as compared with baseline levels. Our data indicate that STEMI is associated with a peripheral expansion of CD4+IL-10+ T lymphocytes, and that primary coronary revascularization with implantation of either BS or PES is followed by a reduction in circulating CD4+IFN-gamma+ T lymphocytes. PES implantation, however, appears to inhibit the relative decrease of the IL-10 producing lymphocyte as observed in BS implanted patients, shifting the balance between pro-inflammatory and anti-inflammatory T cell populations in favor of the latter.
authors.affiliation: Department of Cardiovascular and Respiratory Sciences, La Sapienza University, Rome, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Sardella
authors.forename: L
authors.initials: L
authors.lastname: De Luca
authors.forename: V
authors.initials: V
authors.lastname: Francavilla
authors.forename: D
authors.initials: D
authors.lastname: Accapezzato
authors.forename: A
authors.initials: A
authors.lastname: Di Roma
authors.forename: O
authors.initials: O
authors.lastname: Gianoglio
authors.forename: R
authors.initials: R
authors.lastname: Colantonio
authors.forename: M
authors.initials: M
authors.lastname: Mancone
authors.forename: F
authors.initials: F
authors.lastname: Fedele
authors.forename: M
authors.initials: M
authors.lastname: Paroli
mesh_terms: D054058:Acute Coronary Syndrome / Q000378:metabolism*; D000208:Acute Disease; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000627:therapeutic use; D015496:CD4-Positive T-Lymphocytes / Q000378:metabolism*; D054855:Drug-Eluting Stents; D004562:Electrocardiography; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis* / Q000235:genetics; D016753:Interleukin-10 / Q000096:biosynthesis* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000378:metabolism*; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use; D015607:Stents
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D016753:Interleukin-10; D007371:Interferon-gamma; D017239:Paclitaxel